Bioactive Heterometallic Cu(II)–Zn(II) Complexes with Potential Biomedical Applications

[Image: see text] A series of multinuclear heterometallic Cu–Zn complexes of molecular formula [(CuL)(2)Zn(dca)(2)] (1), [(CuL)(2)Zn(NO(3))(2)] (2), [(CuL)(2)Zn(2)(Cl)(4)] (3), and [(CuL)(2)Zn(2)(NO(2))(4)] (4) have been synthesized by reacting [CuL] as a “metalloligand (ML)” (where HL = N,N′-bis(5-chloro-2-hydroxybenzylidene)-2,2-dimethylpropane-1,3-diamine) and by varying the anions or coligands using the same molar ratios of the reactants. All of the four products including the ML have been characterized by infrared and UV–vis spectroscopies and elemental and single-crystal X-ray diffraction analyses. By varying the anions, different structures and topologies are obtained which we have tried to rationalize by means of thorough density functional theory calculations. All of the complexes (1–4) have now been applied for several biological investigations to verify their therapeutic worth. First, their cytotoxicity properties were assessed against HeLa human cervical carcinoma along with the determination of IC(50) values. The study was extended with extensive DNA and protein binding experiments followed by detailed fluorescence quenching study with suitable reagents to comprehend the mechanistic pathway. From all of these biological studies, it has been found that all of these heterometallic complexes show more than a few fold improvement of their therapeutic values as compared to the similar homometallic ones probably because of the simultaneous synergic effect of copper and zinc. Among all of the four heterometallic complexes, complex 3 exhibits highest binding constants and IC(50) values suggest for their better interaction toward the biological targets and hence have better clinical importance.